ischemic cardiomyopathy

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

ischemic cardiomyopathy

Cardiology A disorder caused by myocardial hypoxia, which compromises the heart's ability to efficiently pump blood; IC may cause heart failure and is a complication of cardiac ischemia, especially affecting older ♂, a disparity that ↓ with advancing geezhood Risks factors Personal or family Hx of MI, angina, unstable angina, ASHD, or other CAD; HTN, smoking, DM, high fat diet, ↑ cholesterol, obesity, stress can all precipitate IC Management rGH improves hemodynamics, clinical function. See Growth hormone.

Mentioned in ?

References in periodicals archive ?

1 However there are very few studies to evaluate other functions of atorvastatin except for blood lipid concentration reduction and the effect of different doses of atorvastatin usage that related to oxidative stress and cardiac function among ischemic Cardiomyopathy (ICM) patients.

Efficacy of different doses of atorvastatin treatment on serum levels of 8-hydroxy-guanin (8-OHdG) and cardiac function in patients with ischemic cardiomyopathy

A review of the Ischemic Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

Ischemic Cardiomyopathy - Pipeline Review, H1 2013 - New Market Study Published

Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy.

Influence of myocardial viability on responsiveness to cardiac resynchronization in ischemic dilated cardiomyopathy: a prospective observational cohort study/Iskemik dilate kardiyomiyopatide kardiyak resenkronizasyon yanitlarina miyokart canliliginin etkisi: bir prospektif gozlemsel kohort calismasi

The Phase 1/2 POSEIDON study enrolled 31 patients with chronic ischemic left ventricular (LV) dysfunction due to ischemic cardiomyopathy (ICM).

Positive Results from Phase 1/2 POSEIDON Trial Demonstrate Donor (Allogeneic) Adult Mesenchymal Stem Cells (MSCs) Utilizing BioCardia Catheter Delivery System Are Similarly Effective as Patients' Own Stem Cells in Treating Ischemic Heart Failure

BioVentrix has shown in multiple clinical trials in Europe that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy and heart failure symptoms results in substantial improvements in LV volume, NYHA Class, 6 minute walk tests, and Quality of Life.

US FDA Clears BioVentrix for Pivotal Clinical Trial

Past trials with ixmyelocel-T have shown better results in patients with ischemic cardiomyopathy than in those with nonischemic cardiomyopathy, a form of heart disease that is caused by heart muscle disorders, so the new trial enrolled only patients with ischemic cardiomyopathy.

Stem cell therapy improves outcomes in severe heart failure

A standardized definition of ischemic cardiomyopathy for use in clinical research.

Selection of candidates for cardiac resynchronization therapy: late gadolinium enhanced cardiac magnetic resonance as a new and promising predictor of intraventricular dyssynchrony/Kardiyak resenkronizasyon tedavisi adaylarinin secimi: Intraventrikuler dissenkroninin yeni ve umit verici ongordurucusu olarak gec gadolinyum tutulumlu kardiyak manyetik rezonans

Type Subtypes Cardiomyopathies Hypertrophic cardiomyopathy Dilated cardiomyopathy Restrictive cardiomyopathy Arrhythmogenic right-ventricular cardiomyopathy Unclassified Specific Ischemic cardiomyopathy cardiomyopathies Valvular cardiomyopathy Hypertensive cardiomyopathy Inflammatory cardiomyopathy Myocarditis Idiopathic Infective Autoimmune Metabolic cardiomyopathy Endocrine Familial storage disease and infiltrations Deficiency Amyloidosis General system disease Connective tissue disorders Infiltrations and granulomas Muscular dystrophies Neuromuscular disorders Sensitivity and toxic reactions Peripartal cardiomyopathy Table 2.

MRI viability imaging for cardiomyopathies

MIs cause fatal dysrhythmias, ischemic cardiomyopathy (i.

Consider benefits of statins

MIs cause fatal dysrhythrnias, ischemic cardiomyopathy (i.

Don't undersell statins' benefits

GlobalData's clinical trial report, Ischemic Cardiomyopathy Global Clinical Trials Review, H1, 2012" provides data on the Ischemic Cardiomyopathy clinical trial scenario.

Research and Markets: Ischemic Cardiomyopathy Global Clinical Trials Review, H1, 2012

BioVentrix has shown that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy heart failure results in substantial improvements in Quality of Life.

First-In-Man, Catheter-Based Endovascular Clinical Procedure Occurs with BioVentrix's Revivent-TC System for Heart Failure Treatment